Navigation Links
Cequent Names Ted Hibben Chief Business Officer
Date:1/12/2009

CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Ted Hibben has joined the company as chief business officer. Mr. Hibben comes to Cequent from Coley Pharmaceutical Group, where he was most recently vice president of business development and alliance management and played a key role in the company's $233 million acquisition by Pfizer in 2008. Coley was a publicly traded biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, asthma, infectious diseases, and autoimmune diseases.

"Strategic partners have been key to Cequent's success to date and will become even more important as we continue to move our tkRNAi technology from the laboratory into clinical development against multiple diseases. Ted brings to Cequent a wealth of experience orchestrating a full range of strategic collaborations with leading pharmaceutical and biotech companies - from drug discovery, research, and clinical-development partnerships to licensing agreements," said Cequent President and CEO, Peter Parker. "Beyond his role in the Pfizer acquisition, Ted's recent track record includes closing nearly a dozen alliances totaling $750 million of itemized pre-commercial development milestones with companies like Novartis, GSK, and Merck."

Regarding Mr. Hibben's role at Cequent, Mr. Parker said, "Ted will focus on external partnering activities in three major areas. On our inflammatory bowel disease (IBD) program, he will look for partner(s) to further develop one or more of the 11 targets we are working on for Crohn's disease and ulcerative colitis; he will also seek to partner our CEQ508 candidate for FAP, slated for a Phase I clinical trial in 2009. FAP (familial adenomatous polyposis) is an inherited precursor to
'/>"/>

SOURCE Cequent Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
2. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
3. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
4. Clarus Ventures Names Two New Partners
5. Xceleron Names Michael Butler as President & CEO
6. Genome Technology Names 2008 Tomorrows PIs
7. Octapharma Names Dennis D. Curtin To Lead U.S. Plasma Operations
8. USP Names Matthew Heyman Vice President of External Affairs and Strategic Integration
9. LCA-Vision Names Michael J. Celebrezze CFO
10. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
11. Great Basin Scientific, Inc. Names Laurence Rea as Vice President of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market ... their offering. The global companion diagnostics ... 22.7% from 2014 to 2019. Factors such as rising ... of companion diagnostics by the pharmaceutical industry, support from ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
(Date:9/18/2014)... Skeletal dysplasia is a group of rare diseases ... and cartilage. Its onset hits at the fetal ... mutation in the gene encoding fibroblast growth factor ... types of skeletal dysplasia, thanatophoric dysplasia (TD), a ... birth and is often lethal, and achondroplasia (ACH), ...
(Date:9/18/2014)... The quest for the ultimate memory device for computing ... at The City College of New York led by ... exhibit both magnetic and ferroelectric properties. , Combining both ... can occur between them and for the devices that ... Combining these two properties in a single material, however, ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Oxides discovered by CCNY team could advance memory devices 2
... Amgen (Nasdaq: AMGN ) today announced that ... financial results on Monday, Jan. 24, 2011 after the close ... a conference call with the investment community at 2:00 p.m. ... Kevin Sharer, chairman and chief executive officer, and other members ...
... 2011 Sensus Healthcare is pleased to ... professional skin care products to be exclusively offered by ... Cases of skin cancer are on the rise and ... taking new aim at skin cancer (SM) in ...
... 2011 Cephalon, Inc., (Nasdaq: CEPH ) will hold ... founder and late Chairman and CEO on February 1, 2011, at ... Street, Philadelphia, Pennsylvania. Dr. Baldino founded Cephalon in ... one of the top ten biotechnology companies in the world. He ...
Cached Biology Technology:Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results 2Sensus Healthcare Announces New Professional Skin Care Line - Sensus Skin Solutions™ 2Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D. 2
(Date:9/18/2014)... invisible is probably the ultimate form of camouflage: you ... And this strategy is not as uncommon as you ... Baltimore County, USA, explains that the larval life stages ... one part of the anatomy that most creatures cannot ... eyes have to shield each individual eye unit with ...
(Date:9/17/2014)... UCLA atmospheric scientists were instrumental in the creation of ... tool to classify the fire threat potential of the ... a spark into an inferno. The index was introduced ... with UCLA and San Diego Gas and Electric. , ... to "extreme" that will be used to help fire ...
(Date:9/17/2014)... genetic disorder known as Jacobsen syndrome has been linked ... researchers at San Diego State University and the University ... treatment options for people with Jacobsen syndrome, the finding ... autism., Jacobsen syndrome affects approximately 1 in 100,000 people, ... in a person when there is a deletion at ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2A link between Jacobsen syndrome and autism 2
... is difficult to measure accurately each nation,s contribution of carbon ... the ground as coal, gas, and oil, and these fuels ... to generate the energy that is used to make products. ... countries where they are consumed. A team led by Carnegie,s ...
... The University of Texas at Austin whose technology developments in ... tens of thousands of patients with diseases such as cancer ... Institute of Medicine (IOM). Established in 1970, IOM is ... institute is considered one of the highest honors in health ...
... of spinal cord injury is receiving attention in the ... the department of biomedical engineering at NJIT, recently has ... micro-electrical stimulators for individuals with spinal cord injuries. ... year of support from a four-year, $1.4 million National ...
Cached Biology News:Links in the chain: Global carbon emissions and consumption 2UT professor elected to the Institute of Medicine of the National Academies 2UT professor elected to the Institute of Medicine of the National Academies 3NJIT researcher testing micro-electronic stimulators for spinal cord injuries 2
Fas-ligand rabbit polyclonal antibody...
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
Biology Products: